Catalog No.
DHA30101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
NRP1, Neuropilin-1, VEGF165R, NRP, CD304, Vascular endothelial cell growth factor 165 receptor
Concentration
1.37 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O14786
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MNRP1685A, CAS: 1205533-60-3
Clone ID
Vesencumab
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans, PMID: 22707361
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors, PMID: 24604265
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice, PMID: 22074316
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors, PMID: 24633809
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors, PMID: 22962439
Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation., PMID:35078508
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors., PMID:24633809
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors., PMID:24604265
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors., PMID:22962439
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans., PMID:22707361
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice., PMID:22074316
For research use only. Not for human or drug use.
